Archive for the ‘nature publishing group’ Category
Earlier this year, we reported on the retraction of a paper because of sloppy work by an outside lab. Now, we have the story of a retraction for “negligence” by a translator. Specifically, the author says the passages shared between the retracted 2015 vascular paper and another paper in EMBO Journal are a result of “negligence on the part of the translation company that I trusted to make my manuscript ready for submission.”
Sauer had two papers retracted from Science last year following a university investigation. Here’s the Nature notice for “Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1:” Read the rest of this entry »
Ryousuke Fujita, a former Columbia University postdoc who admitted to having faked the findings of a 2011 Cell paper in a retraction notice last year, also faked the results of a 2013 Nature paper, according to a new report from the Office of Research Integrity (ORI).
Fujita’s work, in conjunction with Asa Abeliovich, was widely hailed as a significant step forward, a way to turn skin cells into brain cells. But the story began falling apart when the Cell retraction said that he “acknowledged inappropriately manipulating image panels and data points, as well as misrepresenting the number of repeats performed.”
The ORI’s findings in the case also involve a 2013 Nature paper, “Integrative genomics identifies APOE ε4 effectors in Alzheimer’s disease,” and a paper never published. Fujita, according to the ORI: Read the rest of this entry »
David Vaux, a cell biologist at the Walter + Eliza Hall Institute of Medical Research in Melbourne, explains how Nature could do more to remove bias from the peer review process. He previously wrote about his decision to retract a paper.
Last week, Nature announced that they are to offer authors of papers submitted to Nature or the monthly Nature research journals the option of having their manuscripts assessed by double-blind peer review, in which reviewers are blinded to the identity of authors and their institutions. Until now, papers sent to Nature, and most other journals, have been reviewed by a single-blind process, in which the reviewers know the identities and affiliations of the authors, but the authors are not told who the reviewers are. The goal of double-blind peer review is for submitted papers to be judged on their scientific merit alone, and thus to reduce publication bias.
While Nature should be applauded for this move, the way they have implemented it leaves room for improvement.
Quantum communication involves sending a series of photons in specific quantum states over fiberoptic cables. It’s a little like the 1s and 0s of traditional computing, but much more secure. If the photons are intercepted on their way to the intended target, the quantum states will change, and the recipients can know their information was accessed by other parties. This is especially interesting to governments with a lot of secret information to transmit: both China and the U.S. have programs to develop these networks.
The retracted paper was a discussion of how to efficiently send lots of quantum information from different sources through the same fiberoptic cables at once.
Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.
Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.
The notice is clear on the problems with the science, which together “call into question the main conclusions of the paper.” Three of the paper’s five authors were employed at Novartis at the time of publication.
Former University of Tokyo researcher Shigeaki Kato continues to put big numbers on the board.
Last month, we reported on his 26th, 27th, and 28th retractions, all in Nature Cell Biology and cited close to 700 times. Yesterday, EMBO Journal and EMBO Reports published a total of five more retractions for the endocrinology researcher, who resigned from the university in 2012 following investigations found he had faked images.
Nature has issued an Expression of Concern for a paper co-authored by a scientist who threatened to sue us last year for writing about another Expression of Concern for one of his other papers.
Here’s the “Editorial Expression of Concern” for “Non-adaptive origins of interactome complexity:”